Your search matched 10 results
Learn about why it's still important to consider a human approach in healthcare communications from Jeanine O'Kane, President, Public Relations Group at inVentiv Health Communications.
Dramatic changes in U.S. healthcare over the last few years have forced a rethinking of the partnerships pharmaceutical companies form with groups representing patients and families.
PATIENT PARTNERS IN ONCOLOGY | Perspectives
Noticing important shifts in the rules of engagement between industry and patient advocates, Syneos Health Public Relations Group conducted in-depth interviews with dozens of patient organizations in early 2015.
Since the fall of 2015, and against a backdrop of harsh media attention to pharmaceutical pricing, patient advocacy groups that form partnerships with pharma companies have received negative coverage in The New York Times, USA Today and other publications.
Our PR Group is just back from Strengthening Patient Advocacy Relations Conference where Meg Alexander, Head, Reputation & Risk Management & Chris Iafolla, Head, Digital & Social Strategy, presented “Worlds Colliding: When Patient Activism Meets Pharma’s Digital Channels".
SHARING THE MISSION TO CONQUER RARE DISEASES | Perspectives
At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases.
AN ADVOCACY RX FOR PROGRESS IN MENTAL HEALTH | Perspectives
As a source of human suffering, a barrier to workplace productivity, a burden on families and a driver of medical costs, mental illness amounts to an unparalleled public health crisis.
Mental Health: An Insurance Industry Perspective | Perspectives
In more than 15 hours of interviews, executives at managed care organizations covering more than 59 million lives talked about issues that are top of mind for mental health patients, including medication access and psychiatric care.
The pharmaceutical industry recognizes that consumer behavior is a key to both better individual health outcomes and greater business success, and has created a wide range of programs to engage and support patients who are taking prescribed medication.
Health insurers have raised challenging questions about how drugs for rare diseases are defined, regulated, and priced in the U.S. market.